Patients living with multimorbidity (defined as two or more conditions and taking 10 or more regular medicines) Other
Conditions
Interventions
This three-arm cluster randomised trial has two intervention arms: (1) MyComrade, and (2) LinkMM, and a control arm. Aligning with the cluster randomisation trial procedure, the recruited practices wi
Sponsors
Trinity College Dublin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults enrolled in the Chronic Disease Management (CDM) Programme 2. Living with two or more chronic conditions 3. Taking at least 10 regular medicines
Exclusion criteria
Exclusion criteria: Current participant exclusion criteria as of 24/04/2025: 1. Unable to provide informed consent based on language or serious cognitive impairment 2. Limited life expectancy (less than the intervention duration and follow-up period) Previous participant exclusion criteria: 1. Unable to provide informed consent based on language or serious cognitive impairment 2. Have participated in a link worker social prescribing intervention in the previous three years 3. Have met with a GP-based pharmacist in the previous three years 4. Limited life expectancy (less than the intervention duration and follow-up period) 5. Residing in nursing homes and residential care facilities or who are housebound, as these people will not be attending their GP for an in-person CDM review.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following primary outcome measures are assessed at baseline and 6 months: 1. The number of medicines per patient in the MyComrade arm measured using data recorded in patients' medical records to count the number of medicines stopped and started per patient reviewed 2. Patient capability and well-being in the LinkMM arm measured using the ICEpop CAPability measure for Adults (ICECAP-A) | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 23/05/2025: The following secondary outcome measures are assessed in both MyComrade and LINKMM arms at baseline and 6 months follow-up: 1. Patient-Reported Outcomes: 1.1. Quality of life is measured using the EQ-5D-5L questionnaire at baseline and 6 months. 1.2. Mental health is measured using the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) at baseline and 6 months. 1.3. Treatment burden is measured using the Treatment Burden Questionnaire at baseline and 6 months. 1.4. Patient experience of care is measured using the Patient Assessment of Chronic Illness Care (PACIC) questionnaire at baseline and 6 months. 1.5. Patient activation is measured using the Patient Activation Measure (PAM) at baseline and 6 months. 2. Medication-Related Outcomes: 2.1. Medicines outcomes are measured using patient records at baseline and 6 months. 2.2. Number of repeat medications is measured as a numeric count of medications using patient records at baseline and 6 months. 2.3. Potentially inappropriate prescribing (PIP) is measured as a count of flagged prescriptions identified by research pharmacists through review of repeat prescriptions in patient records at baseline and 6 months. 2.4. High-risk prescriptions are measured as a count of flagged prescriptions identified by research pharmacists through review of repeat prescriptions in patient records at baseline and 6 months. 3. Healthcare Utilisation: 3.1. General practitioner (GP) use is measured as the number of in-person and virtual GP visits using patient records at baseline and 6 months. 3.2. GP nurse visits are measured as the number of visits using patient records at baseline and 6 months. 3.3. Emergency department visits are measured using the number and dates of visits from patient records and self-report (in the previous 6 months) at baseline and 6 months. 3.4. Hospital admissions are measured using the number and rates of admission, length of stay, and time to first/re-a | — |
Countries
Ireland
Contacts
Public ContactSusan;Farah Smith;Tahsin
;
Outcome results
None listed